A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type

A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type

Item

http://www.wikidata.org/entity/Q37257445

Q37257445

about

New Pathogenic Concepts and Therapeutic Approaches to Oxidative Stress in Chronic Kidney Disease Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice.Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis.Ipragliflozin Improves Glycemic Control and Decreases Body Fat in Patients With Type 2 Diabetes Mellitus.The effect of cholesteryl ester transfer protein on pancreatic beta cell dysfunction in mice Impact of Reduced Renal Function on the Glucose-Lowering Effects of Luseogliflozin, a Selective SGLT2 Inhibitor, Assessed by Continuous Glucose Monitoring in Japanese Patients with Type 2 Diabetes Mellitus An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study.Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study.Ipragliflozin , a sodium-glucose cotransporter 2 inhibitor, in the treatment of type 2 diabetes.Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease.Safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): Interim results of a post-marketing surveillance study.The effect of SGLT2 inhibitors on cardiovascular events and renal function.Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.Real-world evidence for the safety of ipragliflozin in elderly Japanese patients with type 2 diabetes mellitus (STELLA-ELDER): final results of a post-marketing surveillance study.Efficacy and safety of ipragliflozin as add-on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi-centre, randomized, placebo-controlled, double-blind study.Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.Efficacy of ipragliflozin as monotherapy or as add-on therapy with other oral antidiabetic medications for treating type 2 diabetes in Japanese patients with inadequate glycemic control: A subgroup analysis based on patient characteristics.No disparity of the efficacy and all-cause mortality between Asian and non-Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: A meta-analysis.

P2860

Q26739475-207B4536-A900-4158-9034-253E1F02D308 Q30248634-D2DCFA3D-A9F6-4660-8118-03C562B5AC57 Q31117903-C50CCDB1-7B92-4392-8F37-541897A0E112 Q32186373-35FE60B4-9ECE-4DD4-9F49-AC3C53492286 Q33763305-9D1E0A23-80CE-49E8-BEEE-271931B2CAED Q36679114-F0693AA5-348E-4EB9-8834-EA9158105ED9 Q36804248-C8DFD0CF-9033-44DB-BD7B-2C6E9108EFC4 Q37114983-7C79FC6E-4C61-427B-BF64-0F16DCCB9DA7 Q37251449-6EB8FD6B-2C41-4E35-B2D7-CBE8F7B5F0F0 Q37559899-59369103-5EFF-4061-84E1-F45E5272F9E3 Q38340949-7212E849-B3F3-42BD-B16E-D4F9D738BF96 Q38389823-2ED801A7-D2C5-4B8A-B4BB-BB20AF54E8F7 Q38396879-775D6473-3613-427E-AAE4-7DF46AA05EA5 Q38614488-1C0FEB76-21CD-4F7A-8C34-2F925C087C63 Q38762808-078D52D2-8F42-4FB7-9503-794AE593F0BE Q39540260-6365E4AE-107D-409E-804F-491CF0ED986A Q40606871-D33A18DD-C742-4A4D-B434-214DDB692901 Q47398293-E49049BA-5545-4052-A98B-71ADA1BFD408 Q47995019-7BAAE0C0-BD50-4924-B0BD-21EB318D5FB3 Q48189020-117B399B-1D38-48DA-9C8D-83C8ABB96D5E

P2860

A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type

Item

http://www.wikidata.org/entity/Q37257445

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on February 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs